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Abstract
Introduction: The aim of the present study was to evaluate the clinical outcome of a normal stress technetium-99m 
(99mTc)-Sestamibi single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) with 
different probabilities of coronary artery disease (CAD).
Material and Methods: A total of 1,047 subjects with a normal 99mTc-MIBI SPECT were followed up for one year and 
hard and soft cardiac events were assessed. Hard cardiac events were defined as cardiac death or non-fatal myocardial 
infarction (MI). Soft cardiac events included the patient’s development of recurrent chest pain requiring coronary 
revascularization or significant stenosis in coronary arteries on angiography. 
Results: Overall, 1,047 patients (248 men and 799 women; mean age: 60.07 ± 12.31, range 29–92) were enrolled. Three 
hard cardiac events occurred in the groups; two had cardiac arrest and one non-fatal MI.  As a result, the annualized hard 
cardiac event rate was 0.28%, the annualized cardiac mortality rate was 0.19%, and the rate of overall annualized cardiac 
events was 1.25%. Furthermore, there was a significant difference in cardiac events among patients with various pretest 
likelihoods of CAD (p value=0.04).
Conclusion: Our data confirmed that patients with a normal 99mTc-Sestamibi myocardial SPECT are associated with a 
very low incidence of cardiovascular events.
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Introduction
Myocardial perfusion imaging (MPI) with exercise or 
pharmacological stress, either with thallium-201 (201Tl) 
or technetium-99m (99mTc)-Sestamibi, determines 
important prognostic information for the risk of cardiac 
events in the following 1–2 years and facilitates the accu-
rate management of high-risk patient groups1.
It has been reported that a normal stress 99mTc-
MIBI scan has a benign prognosis, with an annual 
adverse event rate of less than 1%2. Previous studies 
with 99mTc-Sestamibi have assessed the worth of a nor-
mal scan result3-6; however, the acquired data had some 
degree of limitation, such as the use of planar studies3, 
patients with low probability of coronary artery disease 
(CAD)5, small sample size, and short-term follow up3-5. 
We aimed to evaluate the clinical outcome of a normal 
stress 99mTc-Sestamibi SPECT MPI in a large group 
of patients with different pretest likelihoods of CAD. 
We also tried to assess some parameters that affect 
this prognosis.
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The study comprised 1,047 patients with known or sus-
pected CAD referred for myocardial perfusion imaging 
who had a normal stress 99mTc-MIBI SPECT between 
November 2006 and June 2009. None of the patients 
had previous coronary artery bypass surgery (CABG) 
or percutaneous coronary intervention (PCI). Patients 
were collected from the largest social security hospital 
in Iran. 
A questionnaire that included demographics and risk 
factors for CAD was filled out for each patient. The risk 
factors of CAD include: (1) hypertension (systolic blood 
pressure≥140 mmHg or diastolic blood pressure≥90 
mmHg or receiving antihypertensive drugs); (2) fasting 
blood sugar (FBS)≥126 mg/dl or receiving hypoglycemic 
agents; (3) dyslipidemia (low-density lipoproteins (LDL)) 
>130 mg/dl or high-density lipoproteins (HDL)<35mg/
dl or TG≥200 mg/dl); (4) smoking; (5) positive familial 
history (myocardial infarction [MI] or sudden death 
before the age of 55 for males and 65 for females among 
first relatives); (6) body mass index≥30 kg/m2. In addi-
tion, the pretest likelihood of CAD was estimated by 
means of nomograms that correlated the presence of 
diabetes with age, the ratio of cholesterol to HDL, gen-
der, and smoking7. 
The study complies with the Declaration of Helsinki 
and was approved by the institutional ethics committee 
of Shaheed Beheshti University of Medical Science; all 




Overall, 657 patients fasted overnight and all cardiovas-
cular medications were discontinued at least two days 
before the study. An intravenous line of normal saline 
solution was connected to an antecubital vein using a 20 
gauge cannula. Dipyridamole (0.56 mg/kg) was infused 
over 4 minutes. Patient symptoms and three-lead ECG 
were monitored continuously. A dose of 740 MBq of 
99mTc-Sestamibi as a compact bolus was injected 4 min 
after initiation of the infusion. Sixty minutes later, the 
patients were asked to eat a fatty meal to accelerate hepa-
tobiliary clearance of 99mTc-Sestamibi and imaging was 
performed 90 minutes after the initial infusion of dipyri-
damole. The rest phase was performed on the next day.
Technetium	99m	Sestamibi	SPECT	exercise	protocol
After the same precautions as for the dipyridamole test, 
386 patients were asked to exercise on a treadmill under 
a standard Bruce protocol. At the achieved peak heart 
rate (more than 85% of the age-predicted maximum 
heart rate), the appearance of typical angina and/or 
positive exercise ECG findings, 740 MBq of 99mTc-
MIBI was injected as a compact bolus. The exercise test 
was considered to be positive if there was a horizontal or 
downsloping ST segment depression of more than 1 
mm for 80 microseconds after the J point. An intrave-
nous line of normal saline solution was positioned in an 
antecubital vein with a 20 gauge cannula. Imaging was 
performed 15–30 minutes after the exercise. On the next 
day, 60 minutes after the injection of 740 MBq 99mTc-
MIBI, the patients were asked to eat a fatty meal to 
accelerate the hepatobiliary clearance of 99mTc-MIBI. 




In four patients, post intravenous infusion of sequen-
tially increasing doses of dobutamine (starting at 10 µg/
kg/min and reaching 40 µg/kg/min), 740 MBq of 99mTc-
MIBI was injected intravenously and a myocardial perfu-
sion scan SPECT was performed in the stress phase as a 
dipyridamole test. The rest phase was also tested on the 
following day.
Acquisition	and	processing	protocols
A double-head SPECT scintillation camera (ADAC 
Vertex, Malpitas, CA, USA) was used to acquire 32 views 
over 180°, using a step-and-shoot method, progressing 
from 45° right anterior oblique to 45° left posterior 
oblique projections. A symmetric 20% energy window 
over the 140 keV 99mTc photopeak and a low energy all 
purpose (LEAP) collimator were used and the data were 
stored in 64 x 64 matrices. Acquisition time was 25 s per 
projection during rest and stress studies.
Processing was performed using a two-dimensional 
Butterworth prefilter and a ramp filter for back projec-
tion to transaxial tomographic images. The projections 
were shown in the vertical and horizontal orientations 
and also the short axis of the left ventricle. For each 
patient, all three stress images were interpreted sepa-
rately in comparison with the same rest image by four 
nuclear medicine specialists. 
Cardiac	catheterization
Cardiac catheterization was performed if clinically 
indicated. Coronary arteriography was performed with a 
monoplane imaging system and recorded on digital 
versatile disc (DVD). Luminal stenosis of >50% was clas-
sified as significant stenosis on coronary angiography.
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Follow-	up	data
Follow-up data were obtained for one year from tele-
phone interviews, hospital records and physician office 
notes, and were complete. Hard cardiac events were 
defined as cardiac death or non-fatal MI. Soft cardiac 
events included the patient’s development of recurrent 
chest pain requiring coronary revascularization or a sig-
nificant stenosis in coronary arteries on angiography. 
Statistical	analysis
Continuous variables are expressed as the mean ± SD 
and categorical variables as the absolute values and per-
centages. The Student’s t-test was used to compare the 
mean difference of the continuous variables between two 
groups. Moreover, the comparison of categorized vari-
ables between the two groups was performed using the 
Chi-squared test. The statistical analysis was performed 
using the Statistical Package for the Social Science (SPSS) 
version 18 (SPSS Inc., Chicago, IL, USA). A p value<0.05 
was considered to be statistically significant.
Results
Patients
Overall, 1,047 patients with normal scan results were eli-
gible for inclusion in the follow- up study. There were 
248 men and 799 (76.31%) women, aged 60.07 ± 12.31 
with a range between 29 and 92 years (Figure 1). In total, 
41.6% of all participants were females less than 60 years 
old. There was no statistically significant difference 
between ages of men and women (60.13 ± 12.49 years 
and 60.05 ± 12.02 years, respectively; p value = 0.93). The 
stress test was obtained by the dipyridamole protocol in 
657 participants; the exercise protocol in 386 subjects; 
and the dobutamine protocol in 4 patients. Risk factors 
for CAD were diabetes mellitus in 203 patients (19.3%), 
cigarette smoking in 91 (8.6%) patients, hyperlipidemia 
in 475 (45.3%) patients, and hypertension in 452 (43.1%) 
patients (Table 1). In addition, 780 subjects (74.5%) had 
a low pretest likelihood of CAD; 100 subjects (9.6%) had 
moderate pretest likelihood of CAD; 106 subjects 
(10.1%) had a high pretest likelihood of CAD; and 61 
patients (5.8%) had a very high pretest likelihood of 
CAD (Figure 2). 
Adverse	cardiac	events
Three hard cardiac events occurred in the groups: two 
men had cardiac arrest at 6 and 11 months after the dipyr-
idamole stress MPI. Therefore, the annualized cardiac 
mortality rate was 0.19%. The third hard cardiac event 
was a non-fatal MI in a woman 10 months after the exer-
cise 99mTc-Sestamibi scan; she had a 90% stenosis of the 
left anterior descending artery which was demonstrated 
on coronary arteriography. As a result, the annualized 
hard cardiac event rate overall for this cohort was 0.28%. 
In addition, three patients underwent coronary artery 
revascularization (2 PCI and 1 CABG). Furthermore, five 
subjects expired due to breast cancer, three due to gastric 
cancers, three due to pneumonia, and one due to stroke. 
Thus, the overall annualized rate of cardiac events, exclud-
ing other causes of mortality, was 1.25%.
In this study, 39 patients who were less than 40 years 
old had no cardiac event; 551 patients in the age range of 
40–60 years had six cardiac events; 407 patients between 
60 and 80 years had six cardiac events; and 50 patients 
Table 1. Patient characteristics
Age  60.07 ± 12.31 years
M/F  248/799





History of MI    9(0.86%)
Risk of CAD Low 780(74.5%)
 Intermediate 100(9.6%)
 High 106(10.1%)
 Very high  61(5.8%)
HLP, hyperlipidemia; HTN, hypertension; DM, diabetes mellitus; 
FH, family history of coronary artery diease; MI, myocardial infarction; 
CAD, coronary artery disease 
Figure 1. Age distribution of subjects: more than 91% were 
between 40 and 80 years of age. 
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over 80 years of age had one cardiac event; there was no 
significant difference in incidence of cardiac events 
among theses age ranges (p=0.78). Likewise, there was no 
significant difference between incidences of cardiac 
events in the two genders (p=0.33). Furthermore, there 
was no significant difference between type of stress and 
incidence of cardiac events (seven cases in the dipyrida-
mole, six cases in the exercise, and zero in the dobutamine 
protocol; p=0.84). There was a significant difference in 
cardiac events among patients with various pretest likeli-
hoods of CAD (p=0.04) (Figure 2). There was a signifi-
cant difference between type of stress and pretest 
likelihood of CAD (Table 2; p=0.00). 
Coronary	angiography	
Cardiac catheterization was performed in 25 patients: 19 
in the dipyridamole group and 6 in the exercise group. 
Ten patients who underwent cardiac catheterization were 
found to have coronary artery stenosis greater than 50% 
(five single, three double, and two multi-vessel diseases). 
In cases with one vessel disease, left anterior descending 
artery stenosis was reported in four patients and left cir-
cumflex stenosis in one patient. In cases with two vessel 
disease, left anterior descending and left circumflex arte-
rial stenosis were reported in all three patients. 
Discussion
The study showed that normal 99mTc-Sestamibi myocar-
dial perfusion imaging gives an excellent prognosis, with 
an annualized hard cardiac event rate of 0.28%. Previous 
studies have established similar results, although some 
had smaller sample sizes, included low risk for CAD6,8, or 
included both planar and SPECT studies2,3. In contrast, our 
patients had various pretest probabilities of CAD and all 
images were acquired using SPECT technology, which cor-
responds to routine practice in nuclear medicine centers. 
In a review of the literature, it was found that a 
number of authors have reported similar results when 
using conventional 99mTc-MIBI myocardial perfusion 
imaging (Table 3). Stratmann et al. found that the annu-
alized hard cardiac event in 521 patients after normal 
exercise Sestamibi SPECT was 0.5%9. Brown et al. found 
a 0.5% annual event rate in 234 patients with normal 
exercise or dipyridamole planar Sestamibi imaging fol-
lowed up for 10 ± 2 months3. Travin et al. evaluated 1,226 
men and 1,151 women with a normal Sestamibi SPECT 
and obtained an annual rate of hard cardiac events of 
1.7% in men and 0.8% in women10.
In another study by Bodenheimer et al., it was noticed 
that a normal stress MPI test had a good prognosis in 
patients with prior revascularization or recent unstable 
coronary syndrome, with a less than 1% rate of hard 
cardiac events in the subsequent 1–2 years11. To sum up, 
six studies in patients with normal MPI, but an abnor-
mal angiography, including 290 cases, just eight events 
occurred and the annual cardiac event rate was 0.9%12. 
On other hand, one of advantages of 99mTc-MIBI 
SPECT images in women is that there are less breast 
attenuation artifacts compared with 201T113, for which 
only a limited number of studies have included a signifi-
cant fraction of female patients, making it difficult to 
assess this issue2,8,14. Our study, which included a signifi-
cant proportion of women (76%), confirms the good 
prognostic value of 99mTc-Sestamibi myocardial per-
fusion imaging in women as compared with men.
As mentioned above, the event rate may be higher after 
a normal pharmacological study relative to a normal 
exercise stress study, resulting from the higher risk status 
of a population not capable of completing exercise stress 
testing15; however, in our study, the cardiac events among 
the three types of stress were not different, which may be 
due to the low total number of cardiac events. Instead, the 
current study demonstrated that the pretest likelihood of 
CAD had a significant association with the incidence of 
cardiac events, even in patients with normal MPI.
Figure 2. Distribution of cardiac events in different categories 
of pretest likelihood of coronary artery disease (CAD).
Table 2. Distribution of types of stress according to pretest 
likelihood of coronary artery disease (CAD)
 Low Moderate High Very high
Dipyridamole 422 61  76 44
Exercise 347 38  28 16
Dobutamine   1  0   1  1
Total 770 99 105 61
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The mean age of the study patients was 60 years and 
more than 43% of patients were older than this, suggest-
ing that a normal Sestamibi scan relates to very few car-
diac events in an elderly population; therefore, the results 
may apply to an older population. 
In summary, these results suggest that coronary angi-
ography may be safely avoided in most patients after one 
year of a normal 99mTc-Sestamibi SPECT scan, thus, it 
promotes cost effectiveness in this issue . 
Limitations
The principal limitation of the current study is the one 
year follow-up period. It is probable that a longer follow-
up may demonstrate dissimilar outcomes; nevertheless, 
preceding investigations have not approved time-related 
cardiac events. However, because 99mTc-Sestamibi imag-
ing is used in routine practice, the current large sample size 
of the study regarding normal 99mTc-Sestamibi cardiac 
imaging might be useful, at least as preliminary data, in 
our country. The other limitation is that we did not com-
pare the prognostic value of a normal MPI with abnormal 
scanning results. However, an annual rate of hard cardiac 
events of 5% to 7% in relation to abnormal Tc-99m-
Sestamibi scans has been reported in previous studies2,8.
Conclusions
Our study emphasizes that those patients with a normal 
99mTc-Sestamibi myocardial SPECT have a very low 
incidence of cardiac events. As a result, myocardial perfu-
sion imaging with 99m Sestamibi SPECT can determine 
an accurate prognosis in patients with suspected CAD.
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